Alzheimer's & dementia (Amsterdam, Netherlands) · 2025
Accrual of Alzheimer's disease pathology as a function of proximity to parental dementia onset.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ziukelis Elina T, Mak Elijah, Ritchie Craig, O'Brien John T, Aarsland Dag, European Prevention of Alzheimer's Disease (EPAD) Consortium
Аннотация
INTRODUCTION: Whether temporal proximity to parental onset of dementia (PPO) can be used to estimate timing of the preclinical stage of sporadic Alzheimer's disease (AD) remains uncertain.
METHODS: We investigated cross-sectionally adults aged > 50 without dementia included in the European Prevention of Alzheimer's Dementia (EPAD) study. PPO was tested as a predictor of quantitative levels of cerebrospinal fluid (CSF) β-amyloid (1-42) (Aβ1-42) in those with a parental history of dementia (n = 688) and of phosphorylated tau (p-tau) and EPAD neuropsychological examination (ENE) subscores in an amyloid positive subgroup (n = 226). Possible interactions were explored.
RESULTS: Shorter PPO predicted lower CSF Aβ1-42 level (β = 9.357; T = 4.161; p < 0.001), interacting with apolipoprotein E (APOE) -𝜀4 carriage in a dose-dependent manner. Concomitant APOE-𝜀2 carriage appeared to provide protection. PPO did not predict p-tau levels or cognitive performance.
DISCUSSION: PPO may provide a valid method of stratifying risk of early AD pathologic change in APOE-𝜀4 carriers, with empirical and clinical applications.
HIGHLIGHTS: Proximity to age of parental dementia onset can predict amyloid accrualThe effect is APOE-𝜀4 dose-dependent and APOE-𝜀2 appears to provide protectionPPO does not appear to predict further advancement along the AD continuumIn the era of anti-amyloid treatments, this may inform timing of amyloid screeningUsed as an empirical metric, PPO could help elucidate the natural history of LOAD.
METHODS: We investigated cross-sectionally adults aged > 50 without dementia included in the European Prevention of Alzheimer's Dementia (EPAD) study. PPO was tested as a predictor of quantitative levels of cerebrospinal fluid (CSF) β-amyloid (1-42) (Aβ1-42) in those with a parental history of dementia (n = 688) and of phosphorylated tau (p-tau) and EPAD neuropsychological examination (ENE) subscores in an amyloid positive subgroup (n = 226). Possible interactions were explored.
RESULTS: Shorter PPO predicted lower CSF Aβ1-42 level (β = 9.357; T = 4.161; p < 0.001), interacting with apolipoprotein E (APOE) -𝜀4 carriage in a dose-dependent manner. Concomitant APOE-𝜀2 carriage appeared to provide protection. PPO did not predict p-tau levels or cognitive performance.
DISCUSSION: PPO may provide a valid method of stratifying risk of early AD pathologic change in APOE-𝜀4 carriers, with empirical and clinical applications.
HIGHLIGHTS: Proximity to age of parental dementia onset can predict amyloid accrualThe effect is APOE-𝜀4 dose-dependent and APOE-𝜀2 appears to provide protectionPPO does not appear to predict further advancement along the AD continuumIn the era of anti-amyloid treatments, this may inform timing of amyloid screeningUsed as an empirical metric, PPO could help elucidate the natural history of LOAD.